Coronary imaging trial zeroes in on plaque risk
A large prospective trial found plaque burden and plaques involving small lumen area are as likely as classically defined vulnerable plaques to trigger a myocardial infarction.
A large prospective trial found plaque burden and plaques involving small lumen area are as likely as classically defined vulnerable plaques to trigger a myocardial infarction.
The Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) trial is the first study of atherosclerosis using multimodality imaging. Principal investigator Dr. Gregg W. Stone and colleagues at New York-Presbyterian Hospital/Columbia University Medical Center studied 700 patients with acute coronary syndromes using angiography, intravascular ultrasound, and virtual histology analysis of IVUS-acquired radiofrequency data.
Most untreated plaques that cause unexpected heart attacks are not mild lesions, as previously thought, but actually have a large plaque burden and a small lumen area, the researchers found. These characteristics were invisible on the coronary angiogram but easily identifiable on IVUS. Findings were released at the 2009 Transcatheter Cardiovascular Therapeutics scientific symposium in San Francisco.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
